Genetic Technologies Plans Scaled Manufacturing of Covid-19 Test
July 15 2020 - 9:38AM
Dow Jones News
By Matt Grossman
Genetic Technologies Ltd. plans large-scale manufacturing of a
test that could predict whether a person is at risk of a severe
course of Covid-19 if infected, the company said Wednesday.
The test could be used to help design quarantine measures
against the disease, and to determine who ought to have the highest
priority for vaccination if a vaccine becomes available, Genetic
Technologies said.
The Australian diagnostics company said it has filed a patent
for the test in Australia, adding that its facilities will have the
capacity to produce 250,000 tests a year. It also will work with
Thermo Fisher Scientific Inc. to create additional global
manufacturing capacity, the company said.
Genetic Technologies also is working toward approval for the
test in the U.S. with the Centers for Medicare and Medicaid
services, the company said.
The company's American depositary receipts climbed more than 25%
to $2.85 in premarket trading Wednesday morning.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 15, 2020 09:23 ET (13:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Genetic Technologies (ASX:GTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (ASX:GTG)
Historical Stock Chart
From Apr 2023 to Apr 2024
